Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Cohen

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 3, 2014
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancerAndre Konski, Joshua E Meyer, Michael Joiner, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2004
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancerSteven J Cohen, James Gallo, Nancy L Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction CancersPeter C Enzinger, Barbara Ann Burtness, Donna Niedzwiecki, et al.
Annals of Surgical Oncology|August 21, 2010
Defining venous involvement in borderline resectable pancreatic cancerYun Shin Chun, Barton N Milestone, James C Watson, et al.
Cancer Biology & Therapy|November 23, 2007
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancerKalyani Narra, Stefanie R Mullins, Hyung-Ok Lee, et al.
Journal of Pancreatic Cancer|June 7, 2021
Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer DiagnosisAmy E McGhee-Jez, Inna Chervoneva, Misung Yi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic CancerEfrat Dotan, Dana B Cardin, Heinz-Josef Lenz, et al.
American Journal of Clinical Oncology|March 18, 2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by ResectionPatrick M Boland, Joshua E Meyer, Adam C Berger, et al.
Journal of Vascular and Interventional Radiology : JVIR|January 24, 2012
Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panelBertrand Janne d'Othée, Constantinos T Sofocleous, Nader Hanna, et al.
JCO Precision Oncology|December 12, 2023
Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based TherapyIda Micaily, Edik M Blais, Randi Carhart, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 3, 2014
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancerAndre Konski, Joshua E Meyer, Michael Joiner, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2004
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancerSteven J Cohen, James Gallo, Nancy L Lewis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction CancersPeter C Enzinger, Barbara Ann Burtness, Donna Niedzwiecki, et al.
Annals of Surgical Oncology|August 21, 2010
Defining venous involvement in borderline resectable pancreatic cancerYun Shin Chun, Barton N Milestone, James C Watson, et al.
Cancer Biology & Therapy|November 23, 2007
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancerKalyani Narra, Stefanie R Mullins, Hyung-Ok Lee, et al.
Journal of Pancreatic Cancer|June 7, 2021
Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer DiagnosisAmy E McGhee-Jez, Inna Chervoneva, Misung Yi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic CancerEfrat Dotan, Dana B Cardin, Heinz-Josef Lenz, et al.
American Journal of Clinical Oncology|March 18, 2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by ResectionPatrick M Boland, Joshua E Meyer, Adam C Berger, et al.
Journal of Vascular and Interventional Radiology : JVIR|January 24, 2012
Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panelBertrand Janne d'Othée, Constantinos T Sofocleous, Nader Hanna, et al.
JCO Precision Oncology|December 12, 2023
Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based TherapyIda Micaily, Edik M Blais, Randi Carhart, et al.
Pageof 11